A Phase 1/ 2 Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia

PURPOSE: The prognosis of patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) remains poor and novel therapies are needed. The proteasome pathway represents a potential therapeutic target. A phase 1 trial of the second generation proteasome inhibitor, ixazomib in combination with ME...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Clin Cancer Res
Главные авторы: Advani, Anjali S., Cooper, Brenda, Visconte, Valeria, Elson, Paul, Chan, Ricky, Carew, Jennifer, Wei, Wei, Mukherjee, Sudipto, Gerds, Aaron, Carraway, Hetty, Nazha, Aziz, Hamilton, Betty, Sobecks, Ronald, Caimi, Paolo, Tomlinson, Benjamin, Malek, Ehsan, Little, Jane, Miron, Alexander, Pink, John, Maciejewski, Jaroslaw, Kalaycio, Matt, de Lima, Marcos, Sekeres, Mikkael A.
Формат: Artigo
Язык:Inglês
Опубликовано: 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6635077/
https://ncbi.nlm.nih.gov/pubmed/30992301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3886
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы